Moore Kuehn Encourages BSTC Investors to Contact Law Firm

New York, New York--(Newsfile Corp. - November 13, 2020) - Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether BioSpecifics Technologies Corp. (NASDAQ: BSTC) agreement to be acquired by Endo International PLC is fair to shareholders.

Under the terms of the agreement, a tender offer expiring on December 2nd was commenced by Endo International to acquire BioSpecifics Technologies for $88.50 per share. The solicitation statement filed with the SEC in support of the acquisition may omit material information regarding the financial metrics and analyses used to evaluate the merger.

Moore Kuehn is investigating whether the BSTC's Board 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:

Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at or telephone at (212) 709-8245. The consultation and case are free with no obligation to you. Moore Kuehn pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Moore Kuehn is a 5-star Google rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please visit

Attorney advertising. Prior results do not guarantee similar outcomes.

Moore Kuehn, PLLC
Justin Kuehn, Esq.
30 Wall Street, 8th Floor
New York, New York 10005

(212) 709-8245

To view the source version of this press release, please visit